Canadian Medical Company Secures Second Ablatherm in North America

EDAP Sonolith Vision Achieves Top Outcomes in Stone Free Rates An October 2006 publication in the Journal of Endourology compared lithotripsy outcomes for the EDAP Sonolith Vision against the Dornier Compact Delta and the Dornier HM-3, widely considered the Gold Standard in lithotripsy outcomes.

Proven Senior Professionals Added in Growth Markets

Clinical Updates Presented From French Luminary Centers, Marketing Programs Attracting Inquiries

Adds to Executive Team for Ongoing Growth, Expansion

EDAP TMS S.A. to Participate in International Urology Conferences LYON, France -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, today announces it is actively participating in the Societe Internationale d'Urologie (SIU)

EDAP and HealthTronics in Discussions Realigning US Market Entry; Ablatherm RPP Success Growing Europe; Lithotripsy Returns to Profitability - Solid Cash Position for Continued Growth

Ablatherm-HIFU featured in UroToday.com Electronic Newsletter EDAP and Ablatherm-HIFU were recently featured in an email distributed by UroToday.com to more than 10,000 urologists advising them of the site's HIFU Resource Center. Urotoday.com, located at http://www.urotoday.com , is one of the top

Recent Studies Confirm Repeatability of Outcomes, Lower Side Effects for Ablatherm-HIFU

Marketing Efforts Advancing Ablatherm-HIFU in Key Global Market